Notably, HDGC, such as several sporadic diffuse types of GC, rarely have the overexpression of human epidermal growth factor receptor-2 (HER-2), which has a low tumor mutational burden and often lacks relevant markers that suggest effective immunotherapy (15). This evidence concerns the gene ERBB2 and neoplasm.